complement c3a human elisa kit (R&D Systems)
Structured Review

Complement C3a Human Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 3 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/complement c3a human elisa kit/product/R&D Systems
Average 94 stars, based on 3 article reviews
Images
1) Product Images from "C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps"
Article Title: C5aR1 signaling triggers lung immunopathology in COVID-19 through neutrophil extracellular traps
Journal: Journal of Clinical Investigation
doi: 10.1172/jci163105
Figure Legend Snippet: Figure 7. Intratracheal instillation with C5a induced lung immunopathology via C5aR1 signaling and NETs. (A) C57/BL6 mice were treated twice with vehicle, DNAse (Pulmozyme, 10 mg/kg, s.c.), or C5aR1 antagonist (DF2593A, 3 mg/kg, orally), 24 hours and 1 hour before the intratracheal instillation of rmC5a (400 ng). (B) Lung slices from the control group or mice challenged with rmC5a and treated with vehicle, DNAse, or C5aR1 antagonist (DF2593A) were stained with H&E for evaluation of histological changes. (C) Quantification of the lung septal area fraction (n = 5/group). (D) Lung slices from the control group or from mice challenged with rmC5a and treated with vehicle, DNAse, or C5aR1 antagonist (DF2593A) were costained for nuclei (DAPI, blue), H3Cit (green), and MPO (red) markers. (E) NET quantification by the MPO-DNA PicoGreen assay in the supernatant of the lung homogenate (n = 5–6/ group). (F) ELISA assays were performed to detect CCL2, CCL3, CCL4, CXCL1, and IL-6 levels in lung homogenate (n = 5–6/group). Data are shown as the mean ± SEM. P values were determined by 1-way ANOVA followed by Bonferroni’s posthoc test (C, E, and F).
Techniques Used: Control, Staining, Picogreen Assay, Enzyme-linked Immunosorbent Assay

![An <t>ELISA</t> assay was performed to measure the concentrations of ( A ) C5a, ( B ) factor Bb, and ( C ) <t>C3a</t> in the BAL fluid from patients with influenza ( n = 16) and patients with COVID- 19 ( n = 16). ( B ) Paired concentrations of ( D ) C5a and ( E ) factor Bb in the plasma and BAL fluid from patients with COVID-19 were determined by ELISA. ( F ) A different cohort from a previously published data set was reanalyzed and the t-SNE analysis of total cells (65,166) from BAL fluid of patients with non-COVID-19 pneumonia ( n = 13) and COVID-19 ( n = 22) is shown. ( G ) Dot plots display the highlighted distribution of C5AR1 for each indicated cell population. ( H ) Violin plots showing the expression levels of C5aR1 in each type of cell from patients with COVID-19 or with non-COVID-19 pneumonia. ( I ) The dot plot depicts the scaled and centered expression of an average cell in each cluster and therefore contains negative and positive values. The average expression reflects the mean expression of C5AR1 in each cluster compared with all other cells. ( J ) Number of cells per cell population [neutrophils (Neu), monocytes/macrophages (Mo/Mac), and dendritic cells (cDC)] that express C5AR1 in the groups of patients with COVID-19 and non-COVID-19 pneumonia. ( K ) Average expression of C5AR1 per cell for each cell population [neutrophils (Neu), monocytes/macrophages (Mo/Mac), and dendritic cells (cDC)] in the groups of patients with COVID-19 and non-COVID-19 pneumonia. Data are shown as the mean ± SEM. P values were determined by 2-tailed unpaired ( A – D , J , and K ) or paired ( D and E ) Student’s t tests followed by Wilcoxon matched-pairs signed rank tests.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_6787/pmc10266787/pmc10266787__jci-133-163105-g247.jpg)